Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CrystalGenomics Eyes COVID-19 Trials As Hopes Rise For Ivaltinostat

Also Seeking Pipeline Alliances

Executive Summary

Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.

You may also be interested in...



As Chloroquine Demand Surges, Bayer Looks To Emergency Use Authorization To Enter US Market

Unlike diagnostics, EUAs for drugs are rare and the fact that there already are FDA-approved competitors for Bayer’s chloroquine phosphate product may make the decision more complicated.

CrystalGenomics Raises Hefty Funds, Gears Up For New Growth In Innovation

Amid increasing exports of new drug Acelex and multiple out-licensing agreements for its investigative oncology drugs, the South Korean biotech is raising sizable new funds via stocks and bonds this year to seek new longer term growth engines by bringing in new drug assets, or seeking M&As and alliances, and speeding up progress of its R&D pipeline in global markets.

Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D

Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer. 

Topics

Related Companies

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel